Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt

Enas El Nadi; Ahmed El Ghoneimy; Maged El Shafiey; Hala Taha; Mohamed Saad Zaghlool; Iman Zaki; Nehal Kamal; Nada Mounir; Manal Amin

doi:doi:10.11648/j.crj.20210901.13

Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt

Enas El Nadi, Ahmed El Ghoneimy, Maged El Shafiey, Hala Taha, Mohamed Saad Zaghlool, Iman Zaki, Nehal Kamal, Nada Mounir, Manal Amin

Published in Cancer Research Journal (Volume 9, Issue 1)

Received: 22 December 2020 Accepted: 11 January 2021 Published: 25 January 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age 5years. Ewing's sarcoma family tumors include classic Ewing’s sarcoma, primitive neuroectodermal tumour and Askin tumor ES is the second most common variety of primary bone cancer in adolescents and young adults. The treatment strategy for ES is characterized by multi-disciplinary collaboration between pediatric oncologists, medical oncologists, radiation oncologists, and orthopedic surgeons. Although the survival rate of ES patients has improved, their prognosis remains unsatisfactory, and the treatment of ES is still challenging specially in age group below 3 years. Patients and methods: A Retrospective study of children below 3 years with a diagnosis Ewing Sarcoma/PNET treated at our CCHE from July 2009 till December 2018. Results: A review of 46 patients with age ranged from 3 months to 3 years, Mean of age was 1.8. Primary site was Osseous and extraosseus in 23 infant patients for each. Main site was mainly axial in 28 cases (60.8%). Cases were treated according to COG protocol. Infantile Ewing sarcoma OS and EFS at 5-years OS were 75.5% and 66.7%. Conclusion: Patients below 3 years represent an unusually young age group. Conclusion: ES/PNET in age below 3 years is a unique age group with a different management and outcome.

Published in	Cancer Research Journal (Volume 9, Issue 1)
DOI	10.11648/j.crj.20210901.13
Page(s)	14-22
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Ewing Sarcoma, Survival, Infants

References

[1]	Rodriguez-Galindo, C, Liu, T, Krasin, MJ, Wu, J, Billups, CA, Daw, NC, Spunt, SL, Rao, BN, Santana, VM, Navid, F. Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies. Cancer 2007; 110: 375–384. Wiley Online Library PubMed Science Google.
[2]	Pizzo, PA, Poplack, DG. Principles and practice of pediatric oncology, 6th edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011. Google Scholar.
[3]	Glass, AG, Fraumeni, JF. Epidemiology of bone cancer in children. J Natl Cancer Inst 1970; 44: 187–199. CAS PubMed Science Google.
[4]	Thalia Wong BS Robert E. Goldsby MD Rosanna Wustrack MD Thomas Cash MD Michael S. Isakoff MD Steven G. DuBois MD, Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age, Pediatric blood and cancer, volume 62, issue 11, 2015 First published: 14 July 2015 https://doi.org/10.1002/pbc.25635 Cited by: 7Funding: None.
[5]	Jin SG1, Jiang XP2, Zhong L2. A Congenital Ewing's arcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature. Pediatr Neonatol. 2016 Oct; 57 (5): 436-439. doi: 10.1016/j.pedneo.2013.11.002. Epub 2014 Jan 27.
[6]	Maria Antonietta De Ioris,, Arcangelo Prete, 2 Raffaele Cozza, Marta Podda, Carla Manzitti, Andrea Pession, Elisabetta Schiavello, Benedetta Contoli, Rita Balter, Franca Fagioli, Gianni Bisogno, Loredana Amoroso, Franco Locatelli, and Roberto Luksch, Ewing Sarcoma of the Bone in Children under 6 Years of Age, PLoS One. 2013; 8 (1): e53223. Published online 2013 Jan 31. Doi: 10.1371/journal.pone.0053223, PMCID: PMC3561359.
[7]	Ozaki T, Diagnosis and treatment of Ewing sarcoma of the bone: a review article, J Orthop Sci. 2015; 20 (2): 250–263, PMCID: PMC436654.
[8]	Susan J. Maygarden M. D. Frederic B. Askin M. D. Gene P. Siegal M. D., Ph. D. L. A. Gilula M. D. Janice Schoppe B. A. Mary Foulkes Ph. D. John M. Kissane M. D. Mark Nesbit M. D. Ewing sarcoma of bone in infants and toddlers. A clnicopathologic report from the intergroup Ewing's study, Cancer journal, Volume71, Issue6, 15 March 1993 (A Clinicopathologic Report from the Intergroup Ewing’s Study).
[9]	Keir A. Ross Niall A. Smyth Christopher D. Murawski and John G. Kennedy, The Biology of Ewing Sarcoma, International Scholarly Research Notices Volume 2013 \|Article ID 759725 \| 7 pages \| https://doi.org/10.1155/2013/759725.
[10]	Eitaro Ishisaka1 & Kenichi Usami1 & Chikako Kiyotani2 & Keita Terashima2 & Hideki Ogiwara, Infantile intraorbital Ewing’s sarcoma: case report and review Of the literature, 2 April 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020.
[11]	Mascarenhas L, Felgenhauer JL, Bond MC, Villaluna D, Femino JD, Laack NN, Ranganathan S, Meyer J, Womer RB, Gorlick R, Krailo MD, Marina N (2016) Pilot study of adding vincristine, topotecan, and cyclophos- phamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: a report from the Children’s Oncology Group. Pediatric Blood Cancer 63 (3): 493–498.
[12]	Upasana S Ahuja, Nidhi Puri, Deepak Gupta, Shivangi Singh, Gyanendra Kumar, Ewing's Sarcoma of Mandible: A Case Report with Review, International Journal of Clinical Pediatric Dentistry 2019, 12 (5): 470-474.
[13]	Samer Salah, Hadeel Halalsheh, Fawzi Abuhijla, et al, The Impact of Local Control Timing in Ewing Sarcoma, January 2020, Reports of Practical Oncology and Radiotherapy 25 (2) DOI: 10.1016/j.rpor.2020.02.001.
[14]	Henk van den Berg 1, Uta Dirksen, Andreas Ranft, Heribert Jürgens, Ewing Tumors in Infants, Pediatric Blood Cancer. 2008 Apr; 50 (4): 761-4. Doi: 10.1002/pbc.21292.
[15]	Karski EE, McIlvaine E, Segal MR, et al.: Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatric Blood Cancer 63 (1): 47-53, 2016. [PUBMED Abstract].
[16]	Ahmed SK, Randall RL, DuBois SG, et al.: Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys 99 (5): 1286-1294, 2017. [PUBMED Abstract].
[17]	Wong T, Goldsby RE, Wustrack R, et al.: Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. Pediatr Blood Cancer 62 (11): 1947-51, 2015. [PUBMED Abstract].
[18]	Vohar VG. Ewing's tumor, a report on 27 cases. Indian J Radiol Imaging. 2008; 18 (2): 106–112. [Google Scholar].
[19]	S Ahrens 1, C Hoffmann, S Jabar, G Braun-Munzinger, M Paulussen, J Dunst, C Rübe, W Winkelmann, A Heinecke, U Göbel, K Winkler, D Harms, J Treuner, H JürgensEvaluation of Prognostic Factors in a Tumor Volume-Adapted Treatment Strategy for Localized Ewing Sarcoma of Bone: The CESS 86 Experience. Cooperative Ewing Sarcoma Study, Med Pediatr Oncol,. 1999 Mar; 32 (3): 186-95. Doi: 10.1002/(sici)1096-911x(199903)32:3<186:aid-mpo5>3.0.co; 2-d.
[20]	Masood Umer, corresponding author Irfan Qadir, Nadeem Abbasi, Jai K Das, and Zohra S Lassi. Radiotherapy for localised Ewing’s sarcoma in children, 2016 Oct; 2016 (10): CD011105.
[21]	Published online 2016 Oct 12. doi: 10.1002/14651858.CD011105.pub2.
[22]	PMCID: PMC6457913.

Cite This Article

Plain Text BibTeX RIS

APA Style

Enas El Nadi, Ahmed El Ghoneimy, Maged El Shafiey, Hala Taha, Mohamed Saad Zaghlool, et al. (2021). Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt. Cancer Research Journal, 9(1), 14-22. https://doi.org/10.11648/j.crj.20210901.13

Copy | Download

ACS Style

Enas El Nadi; Ahmed El Ghoneimy; Maged El Shafiey; Hala Taha; Mohamed Saad Zaghlool, et al. Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt. Cancer Res. J. 2021, 9(1), 14-22. doi: 10.11648/j.crj.20210901.13

Copy | Download

AMA Style

Enas El Nadi, Ahmed El Ghoneimy, Maged El Shafiey, Hala Taha, Mohamed Saad Zaghlool, et al. Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt. Cancer Res J. 2021;9(1):14-22. doi: 10.11648/j.crj.20210901.13

Copy | Download

@article{10.11648/j.crj.20210901.13,
  author = {Enas El Nadi and Ahmed El Ghoneimy and Maged El Shafiey and Hala Taha and Mohamed Saad Zaghlool and Iman Zaki and Nehal Kamal and Nada Mounir and Manal Amin},
  title = {Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt},
  journal = {Cancer Research Journal},
  volume = {9},
  number = {1},
  pages = {14-22},
  doi = {10.11648/j.crj.20210901.13},
  url = {https://doi.org/10.11648/j.crj.20210901.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20210901.13},
  abstract = {Introduction: Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age 5years. Ewing's sarcoma family tumors include classic Ewing’s sarcoma, primitive neuroectodermal tumour and Askin tumor ES is the second most common variety of primary bone cancer in adolescents and young adults. The treatment strategy for ES is characterized by multi-disciplinary collaboration between pediatric oncologists, medical oncologists, radiation oncologists, and orthopedic surgeons. Although the survival rate of ES patients has improved, their prognosis remains unsatisfactory, and the treatment of ES is still challenging specially in age group below 3 years. Patients and methods: A Retrospective study of children below 3 years with a diagnosis Ewing Sarcoma/PNET treated at our CCHE from July 2009 till December 2018. Results: A review of 46 patients with age ranged from 3 months to 3 years, Mean of age was 1.8. Primary site was Osseous and extraosseus in 23 infant patients for each. Main site was mainly axial in 28 cases (60.8%). Cases were treated according to COG protocol. Infantile Ewing sarcoma OS and EFS at 5-years OS were 75.5% and 66.7%. Conclusion: Patients below 3 years represent an unusually young age group. Conclusion: ES/PNET in age below 3 years is a unique age group with a different management and outcome.},
 year = {2021}
}

Copy | Download

TY - JOUR
T1 - Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt
AU - Enas El Nadi
AU - Ahmed El Ghoneimy
AU - Maged El Shafiey
AU - Hala Taha
AU - Mohamed Saad Zaghlool
AU - Iman Zaki
AU - Nehal Kamal
AU - Nada Mounir
AU - Manal Amin
Y1 - 2021/01/25
PY - 2021
N1 - https://doi.org/10.11648/j.crj.20210901.13
DO - 10.11648/j.crj.20210901.13
T2 - Cancer Research Journal
JF - Cancer Research Journal
JO - Cancer Research Journal
SP - 14
EP - 22
PB - Science Publishing Group
SN - 2330-8214
UR - https://doi.org/10.11648/j.crj.20210901.13
AB - Introduction: Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age 5years. Ewing's sarcoma family tumors include classic Ewing’s sarcoma, primitive neuroectodermal tumour and Askin tumor ES is the second most common variety of primary bone cancer in adolescents and young adults. The treatment strategy for ES is characterized by multi-disciplinary collaboration between pediatric oncologists, medical oncologists, radiation oncologists, and orthopedic surgeons. Although the survival rate of ES patients has improved, their prognosis remains unsatisfactory, and the treatment of ES is still challenging specially in age group below 3 years. Patients and methods: A Retrospective study of children below 3 years with a diagnosis Ewing Sarcoma/PNET treated at our CCHE from July 2009 till December 2018. Results: A review of 46 patients with age ranged from 3 months to 3 years, Mean of age was 1.8. Primary site was Osseous and extraosseus in 23 infant patients for each. Main site was mainly axial in 28 cases (60.8%). Cases were treated according to COG protocol. Infantile Ewing sarcoma OS and EFS at 5-years OS were 75.5% and 66.7%. Conclusion: Patients below 3 years represent an unusually young age group. Conclusion: ES/PNET in age below 3 years is a unique age group with a different management and outcome.
VL - 9
IS - 1
ER -

Copy | Download

Author Information

Enas El Nadi

Department of Clinical Oncology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Pediatric Oncology Department, Children Cancer Hospital of Egypt, Cairo, Egypt
Ahmed El Ghoneimy

Orthopedics, Children Cancer Hospital of Egypt, Cairo, Egypt
Maged El Shafiey

Surgical Oncology, Children Cancer Hospital of Egypt, Cairo, Egypt; Surgical Oncology National Cancer Institute, Cairo, Egypt
Hala Taha

Surgical Pathology, Children Cancer Hospital of Egypt, Cairo, Egypt; Surgical Pathology National Cancer Institute, Cairo, Egypt
Mohamed Saad Zaghlool

Radiotherapy Department, Children Cancer Hospital of Egypt, Cairo, Egypt; Radiotherapy Department, National Cancer Institute, Cairo, Egypt
Iman Zaki

Radiology Department, Children Cancer Hospital of Egypt, Cairo, Egypt; Radiology Department, National Cancer Institute, Cairo, Egypt
Nehal Kamal

Clinical Research Department, Children Cancer Hospital of Egypt, Cairo, Egypt
Nada Mounir

Department of Clinical Oncology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Pediatric Oncology Department, National Cancer Institute, Cairo, Egypt
Manal Amin

Pediatric Oncology Department, Children Cancer Hospital of Egypt, Cairo, Egypt; Orthopedics, Children Cancer Hospital of Egypt, Cairo, Egypt

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Enas El Nadi, Ahmed El Ghoneimy, Maged El Shafiey, Hala Taha, Mohamed Saad Zaghlool, et al. (2021). Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt. Cancer Research Journal, 9(1), 14-22. https://doi.org/10.11648/j.crj.20210901.13

Copy | Download

ACS Style

Enas El Nadi; Ahmed El Ghoneimy; Maged El Shafiey; Hala Taha; Mohamed Saad Zaghlool, et al. Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt. Cancer Res. J. 2021, 9(1), 14-22. doi: 10.11648/j.crj.20210901.13

Copy | Download

AMA Style

Enas El Nadi, Ahmed El Ghoneimy, Maged El Shafiey, Hala Taha, Mohamed Saad Zaghlool, et al. Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt. Cancer Res J. 2021;9(1):14-22. doi: 10.11648/j.crj.20210901.13

Copy | Download

@article{10.11648/j.crj.20210901.13,
  author = {Enas El Nadi and Ahmed El Ghoneimy and Maged El Shafiey and Hala Taha and Mohamed Saad Zaghlool and Iman Zaki and Nehal Kamal and Nada Mounir and Manal Amin},
  title = {Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants: A Report from Children Cancer Hospital of Egypt},
  journal = {Cancer Research Journal},
  volume = {9},
  number = {1},
  pages = {14-22},
  doi = {10.11648/j.crj.20210901.13},
  url = {https://doi.org/10.11648/j.crj.20210901.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20210901.13},
  abstract = {Introduction: Ewing sarcoma is an aggressive malignancy of bone and soft tissue. It is rare in children under age 5years. Ewing's sarcoma family tumors include classic Ewing’s sarcoma, primitive neuroectodermal tumour and Askin tumor ES is the second most common variety of primary bone cancer in adolescents and young adults. The treatment strategy for ES is characterized by multi-disciplinary collaboration between pediatric oncologists, medical oncologists, radiation oncologists, and orthopedic surgeons. Although the survival rate of ES patients has improved, their prognosis remains unsatisfactory, and the treatment of ES is still challenging specially in age group below 3 years. Patients and methods: A Retrospective study of children below 3 years with a diagnosis Ewing Sarcoma/PNET treated at our CCHE from July 2009 till December 2018. Results: A review of 46 patients with age ranged from 3 months to 3 years, Mean of age was 1.8. Primary site was Osseous and extraosseus in 23 infant patients for each. Main site was mainly axial in 28 cases (60.8%). Cases were treated according to COG protocol. Infantile Ewing sarcoma OS and EFS at 5-years OS were 75.5% and 66.7%. Conclusion: Patients below 3 years represent an unusually young age group. Conclusion: ES/PNET in age below 3 years is a unique age group with a different management and outcome.},
 year = {2021}
}

Copy | Download